Stoke Therapeutics
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 110
- Market Cap
- $730.2M
- Introduction
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Stoke Therapeutics, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT04740476
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธSeattle Children's Hospital, Seattle, Washington, United States
๐บ๐ธChildren's National Medical Center, Washington, District of Columbia, United States
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome
- Conditions
- Dravet Syndrome
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Stoke Therapeutics, Inc
- Target Recruit Count
- 62
- Registration Number
- NCT04442295
- Locations
- ๐บ๐ธ
UCSF Benioff Children's Hospital, San Francisco, California, United States
๐บ๐ธPrimary Children's Hospital, Salt Lake City, Utah, United States
๐บ๐ธSeattle Children's Hospital, Seattle, Washington, United States